GDTC vs. CPIX, BFRG, BNTC, TXMD, APM, MEIP, RNXT, ORGS, LUMO, and LSTA
Should you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include Cumberland Pharmaceuticals (CPIX), Bullfrog AI (BFRG), Benitec Biopharma (BNTC), TherapeuticsMD (TXMD), Aptorum Group (APM), MEI Pharma (MEIP), RenovoRx (RNXT), Orgenesis (ORGS), Lumos Pharma (LUMO), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical preparations" industry.
Cumberland Pharmaceuticals (NASDAQ:CPIX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 43.3% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Cumberland Pharmaceuticals received 185 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 45.06% of users gave Cumberland Pharmaceuticals an outperform vote.
In the previous week, Cumberland Pharmaceuticals had 8 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 10 mentions for Cumberland Pharmaceuticals and 2 mentions for CytoMed Therapeutics. Cumberland Pharmaceuticals' average media sentiment score of 0.44 beat CytoMed Therapeutics' score of 0.15 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.
CytoMed Therapeutics has lower revenue, but higher earnings than Cumberland Pharmaceuticals.
CytoMed Therapeutics has a consensus price target of $5.00, indicating a potential upside of 129.36%. Given Cumberland Pharmaceuticals' higher possible upside, analysts plainly believe CytoMed Therapeutics is more favorable than Cumberland Pharmaceuticals.
CytoMed Therapeutics has a net margin of 0.00% compared to CytoMed Therapeutics' net margin of -21.67%. CytoMed Therapeutics' return on equity of 0.21% beat Cumberland Pharmaceuticals' return on equity.
Summary
Cumberland Pharmaceuticals beats CytoMed Therapeutics on 7 of the 13 factors compared between the two stocks.
Get CytoMed Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CytoMed Therapeutics Competitors List
Related Companies and Tools
